Single dose of next-generation psilocybin shows significant reduction in depression, with 20% no longer needing treatment | Spotlight on psychedelics
On October 31, 2023, the alternative medicine community woke up to unprecedented positive data demonstrating the safety and effectiveness of psilocybins in the treatment of depression. Cybin, a biotechnology company working on next-generation psychedelic treatments, announced remarkable results from its Phase 2 clinical trial using a proprietary version of deuterated psilocybin for the treatment of …
